Ryboquin

About Ryboquin

Ryboquin Limited is a pharmaceutical company, founded in 2013 and headquartered in Selkirk, Scotland, that specializes in developing gene therapies for cancer treatment. The firm was spun out of an Edinburgh-based medicine developer called Ectopharma. The company's primary focus is on commercializing intellectual property related to gene therapy delivery systems to enhance the efficacy of oncology treatments.

Ryboquin's core technology is centered around its lead product, ECP-102, a Tumour Apoptosis Enhancer (TAE). This product utilizes a nano-particle called LipTide siRNA, which is designed to up-regulate the p73 protein, a component that makes tumor cells more susceptible to death. The company's stated goal is to make chemotherapy treatments significantly more effective. To advance this technology, Ryboquin licensed the LipTide platform from Nanogenics, a spin-out from University College London. In July 2018, Ryboquin raised £4.45 million to acquire Nanogenic Solutions, its English partner, forming a new combined entity named Nanogenics Limited to pioneer safer and more effective dosing of gene therapies. This strategic acquisition combined Ryboquin's product development with Nanogenic's delivery platform.

The company has secured funding through several rounds, including a £1.3 million round in May 2016 from equity and a Scottish Enterprise R&D grant, and a subsequent £1.8 million ($2.3 million) in July 2017. Key investors include the Scottish Investment Bank, angel group TRI Capital, and prominent entrepreneurs Sir Brian Souter, founder of Stagecoach, and Brian Kennedy. As part of the 2017 funding round, Brian Kennedy joined the company's board of directors. Paul Murray serves as the Executive Chairman.

While one source has marked the company as 'deadpooled', official UK government records show 'Ryboquin Company Ltd' as still active. The acquisition of Nanogenic Solutions and renaming to Nanogenics Limited was intended to create a public company in the future, with a focus on licensing its LipTide delivery platform to other biotech firms while also developing its own product pipeline.